In spite of the small number of patients included in this study, the Rapporteur considers that this indication could be acceptable since homozygous familial hypercholesterolemia is a very rare condition and it is a hard-to-treat disease because patients express little or no LDL receptor activity and therefore are resistant to the effects of therapeutic diets and most cholesterol-lowering medications.